Budipine

Jump to: navigation, search
Budipine
Budipine.png
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC21H27N
Molar mass293.446 g/mol
3D model (JSmol)
  (verify)

WikiDoc Resources for Budipine

Articles

Most recent articles on Budipine

Most cited articles on Budipine

Review articles on Budipine

Articles on Budipine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Budipine

Images of Budipine

Photos of Budipine

Podcasts & MP3s on Budipine

Videos on Budipine

Evidence Based Medicine

Cochrane Collaboration on Budipine

Bandolier on Budipine

TRIP on Budipine

Clinical Trials

Ongoing Trials on Budipine at Clinical Trials.gov

Trial results on Budipine

Clinical Trials on Budipine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Budipine

NICE Guidance on Budipine

NHS PRODIGY Guidance

FDA on Budipine

CDC on Budipine

Books

Books on Budipine

News

Budipine in the news

Be alerted to news on Budipine

News trends on Budipine

Commentary

Blogs on Budipine

Definitions

Definitions of Budipine

Patient Resources / Community

Patient resources on Budipine

Discussion groups on Budipine

Patient Handouts on Budipine

Directions to Hospitals Treating Budipine

Risk calculators and risk factors for Budipine

Healthcare Provider Resources

Symptoms of Budipine

Causes & Risk Factors for Budipine

Diagnostic studies for Budipine

Treatment of Budipine

Continuing Medical Education (CME)

CME Programs on Budipine

International

Budipine en Espanol

Budipine en Francais

Business

Budipine in the Marketplace

Patents on Budipine

Experimental / Informatics

List of terms related to Budipine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Budipine is an antiparkinson agent.

Its mechanism of action is not well characterized.[2] It is believed to be an NMDA receptor antagonist,[3] however, promoting the synthesis of dopamine.[4]

Because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment.[5]

See also

References

  1. Martndale: The Complete Drug Reference, 35th Ed.
  2. Reichmann H (October 2006). "Budipine in Parkinson's tremor". J. Neurol. Sci. 248 (1–2): 53–5. doi:10.1016/j.jns.2006.05.039. PMID 16784759.
  3. J. Kornhuber, B. Herr, J. Thome, P. Riederer. "The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue". J.Neural Transm.Suppl. 46:127-133, 1995. PMID 8821048
  4. "umm.edu".
  5. Przuntek H, Bittkau S, Bliesath H; et al. (May 2002). "Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen". Arch. Neurol. 59 (5): 803–6. doi:10.1001/archneur.59.5.803. PMID 12020263.

Linked-in.jpg